2010 - Neural Mechanisms of Ageing and Cognitive Decline
2010 - Neural Mechanisms of Ageing and Cognitive Decline
2010 - Neural Mechanisms of Ageing and Cognitive Decline
Author Manuscript
Nature. Author manuscript; available in PMC 2010 September 1.
Published in final edited form as:
NIH-PA Author Manuscript
Abstract
During the past century, treatments for the diseases of youth and middle age have helped raise life
expectancy significantly. However, cognitive decline has emerged as one of the greatest health
threats of old age, with nearly 50% of adults over the age of 85 afflicted with Alzheimer’s disease.
Developing therapeutic interventions for such conditions demands a greater understanding of the
processes underlying normal and pathological brain ageing. Recent advances in the biology of
ageing in model organisms, together with molecular and systems-level studies of the brain, are
beginning to shed light on these mechanisms and their potential roles in cognitive decline.
Cognitive frailty is emerging as one of the greatest health threats of the twenty-first century.
NIH-PA Author Manuscript
As the life expectancy of the population has increased, so too has the prevalence of
cognitive decline and dementia, largely in the form of Alzheimer’s disease, which now
affects almost 50% of adults over the age of 85 in the United States (1). This startling figure
can only grow as the average age of the population rises, so understanding the basis of
cognitive decline during ageing is critical. The greatest risk factor for cognitive decline and
Alzheimer’s disease in older adults is age itself. Therefore, the development of these
pathologies must be understood in the context of the molecular biology of the ageing
process.
Fortunately, the past 15 years have witnessed a great increase in our knowledge of the basic
molecular mechanisms of ageing. Most remarkably, functional genetic analysis has
identified signalling pathways that act as master regulators of ageing and lifespan and that
are conserved in yeast, nematodes, flies and mammals. Analysis of these model systems
suggests that the rate of ageing is not inevitably fixed but is plastic and open to modification.
Similarly, cognitive decline associated with mammalian brain ageing also seems to be
variable and possibly open to modification (Table 1). An important question is whether age-
related cognitive changes are mediated by any of the master regulators of ageing and
lifespan identified in model organisms. Moreover, recent studies have implicated these
NIH-PA Author Manuscript
pathways in the control of age-related brain pathology, raising the possibility that altered
regulation of fundamental mechanisms of ageing may contribute to the pathogenesis of
neuro degenerative disorders.
Two important technical advances have provided new insight into the biology of brain
ageing. Microarray technology has made global gene expression analysis possible in humans
and model organisms, leading to the identification of evolutionarily conserved changes
during ageing. Concurrently, improvements in functional brain imaging have afforded us an
unprecedented view of the workings of large-scale cognitive networks in the ageing human
brain. An important challenge is to unify these two levels of analysis to obtain a more global
view of brain and organismal ageing in humans.
In this Review, we explore the basic molecular mechanisms of the ageing process in the
brain. We begin with a brief description of large-scale functional alterations in human brain
ageing. Then we turn to a discussion of conserved mechanisms of ageing that may underlie
the changes observed in the ageing brain, with a focus on mitochondrial function and
oxidative stress, autophagy and protein turnover, insulin/IGF signalling, target of rapamycin
Bishop et al. Page 2
(TOR) signalling and sirtuin function. To begin to understand the ageing of the brain in the
context of the entire organism, we discuss how the brain might coordinate the ageing
process by acting as a primary sensor of physiological and environmental stressors through
NIH-PA Author Manuscript
the action of conserved signalling pathways. There is hope that our growing understanding
of the molecular basis of brain ageing and the role of the brain in the ageing body will allow
us to rise to the challenge of treating and preventing cognitive decline and Alzheimer’s
disease.
individuals who exhibit delocalized activity show better cognitive performance than aged
individuals with more localized activity, consistent with the idea that delocalization may be
a compensatory response (3,5). These observations suggest that the higher-order systems
biology of the brain is significantly altered by normal ageing in the absence of disease.
A central question is whether these functional changes, which appear in most ageing
individuals, are clearly distinct from pathological processes associated with
neurodegenerative disorders such as Alzheimer’s disease. Functional magnetic resonance
imaging studies suggest that changes in the activity of the hippocampus and associated
cortical regions can distinguish normal ageing from pathological ageing. Normal ageing is
associated with reduced metabolic activity in the subiculum and the dentate gyrus, whereas
reduced activity in the entorhinal cortex may be an early indicator of Alzheimer’s disease
(14). At the histopathological level, neuronal loss, beginning in the entorhinal cortex and the
CA1 field of the hippocampus, together with volume loss in the medial temporal lobe,
distinguishes normal ageing from the cognitive decline associated with Alzheimer’s disease
(15–18). However, other pathological hallmarks of Alzheimer’s disease (such as synapse
loss, amyloid plaques and neurofibrillary tangles) can correlate with cognitive decline and
become extensive in Alzheimer’s disease but are detected to varying degrees in many aged
individuals in the absence of cognitive decline. To understand the relationship between
Alzheimer’s disease and normal brain ageing, we must gain a greater understanding of the
mechanistic basis of the ageing process. The identification of ageing pathways in model
organisms is beginning to shed light on this fundamental question.
NIH-PA Author Manuscript
of neurodegenerative disorders.
Despite clear evidence of conservation of some ageing pathways and gene expression
signatures, a recent study directly comparing gene expression during ageing in mouse,
rhesus macaque and human brain has revealed a major evolutionary divergence (13). More
than 150 genes were found to undergo age-dependent expression changes in all three
organisms. Not all of these genes changed expression in the same direction in all three
organisms. A significant fraction of age-regulated genes, mostly predicted to participate in
neuronal functions, are upregulated with age in mice but downregulated with age in humans.
This suggests an evolutionary shift since the divergence of the rodent and human lineages,
resulting in coordinate repression, rather than activation, of many neuronal genes during
ageing. Biochemical and stereological neuronal counting studies of the ageing human cortex
suggest that this is unlikely to reflect neuronal loss (6,13). It is important to appreciate the
evolution of these gene expression changes, as they may contribute to the apparent human
specificity of certain neurodegenerative disorders, such as Alzheimer’s disease.
Mitochondrial dysfunction
Gene expression studies suggest that reduced expression of mitochondrial genes is a
NIH-PA Author Manuscript
these experimental models are not entirely clear, one hypothesis is that efficient electron
transport chain function reduces the generation and release of damaging reactive oxygen
species (ROS).
Brain and muscle are particularly susceptible to defective mitochondrial function. The
human mitochondrial encephalomyopathies are inherited disorders caused by deletions or
mutations of mitochondrial DNA. These mitochondrial defects lead to varied neurological
and muscle-related impairments that depend on the number of mitochondria affected per cell
(32,33). Importantly, this dependence on the number of affected mitochondria also regulates
the age of onset of clinical symptoms. Hence, it has been suggested that a normal decrement
in mitochondrial function may also contribute to age-dependent functional deficits in
neurons and myocytes. Evidence in support of this notion comes from studies of Drosophila,
in which the orthologue of the mammalian brain-specific mitochondrial uncoupling protein
UCP5 functions specifically in neurons to regulate metabolism and lifespan (34). In the
human brain, declining mitochondrial function may selectively affect neuronal populations
with large bio energetic demands, such as the large pyramidal neurons that degenerate in
Alzheimer’s disease. Thus, declining mitochondrial function may contribute to brain ageing
and render neurons vulnerable to age-dependent pathology.
NIH-PA Author Manuscript
mouse also exhibits protection against neuronal excitotoxicity in the brain. Although the
signaling mechanisms mediating increased longevity in this context are not well understood,
one possibility is that ROS in a modestly increased concentration act as signalling molecules
to activate survival pathways and promote longevity.
The observation that modestly reduced mitochondrial function can activate longevity
pathways raises the interesting possibility that the initial decline in mitochondrial gene
expression observed during brain ageing may be part of an active compensatory mechanism
that increases stress resistance. Such a compensatory response might be effective in resisting
transient stress. However, persistent stress associated with ageing may further reduce
mitochondrial function, leading to a self-reinforcing cycle of detrimental decline (Fig. 3).
In the ageing human brain, oxidative damage to specific gene promoters results in gene
silencing (7). It may be that irreplaceable post-mitotic cells, such as neurons, respond to
unrepaired DNA damage by silencing expression of the affected genomic region, rather than
by undergoing apoptosis. The mechanism of silencing may be epigenetic; specifically, it
may be a transition to a more repressive transcriptional state (7,13). Recent studies have
shown that DNA damage can induce changes in gene expression and histone modification
patterns that may be mediated, in part, by the conserved lifespan regulatory gene SIRT1 (see
below), suggesting a possible mechanistic link between DNA damage, epigenomic state and
ageing (45,46). Consistent with this idea, the yeast homologue of SIRT1, SIR2, is a long-
NIH-PA Author Manuscript
established regulator of lifespan, DNA damage repair and epigenetic gene silencing (47).
Furthermore, a number of chromatin-remodelling factors regulate lifespan in C. elegans
(48). These considerations argue strongly for a conserved role of epigenome dynamics in the
ageing process.
A recent study demonstrated the importance of altered epigenetic state in the control of brain
neuronal gene expression underlying synaptic plasticity and memory. The study used a
mouse model in which inducible expression of p25, an allosteric regulator of cyclin-
dependent kinase 5 (CDK5), elicits neurodegeneration. A transient period of p25 expression
in the adult mouse resulted in some degree of neurodegeneration and synapse loss in the
hippocampus, together with memory loss (49). Environmental enrichment promoted the
recovery of lost memories, which was accompanied by increased synaptic plasticity and the
induction of activating histone acetylation marks. Remarkably, treatment with a
pharmacological histone deacetylase inhibitor was able to mimic environmental enrichment
and promote neuronal plasticity and recovery of memory function. These findings highlight
the role of epigenetic changes in memory loss associated with neurodegeneration. In
addition, they suggest that loss of memory storage is distinct from loss of neural pathways
that access stored memory. Given that human brain ageing is accompanied by memory loss
NIH-PA Author Manuscript
and reduced synaptic connectivity, but not significantly by neuronal loss, it is probable that
loss of the ability to access stored memories underlies age-dependent memory deficits. If
this is so, there is hope that pharmacological interventions affecting epigenetic state could
ameliorate some of the cognitive deficits associated with ageing and neurodegenerative
disorders.
The signalling pathway of the kinase TOR is a central regulator of protein homeostasis that
acts to inhibit autophagy and messenger RNA translation. Reduced TOR signalling has been
shown to extend lifespan in yeast, worms and flies (reviewed in ref. 57). Moreover, it was
recently shown that the TOR inhibitor rapamycin extends lifespan in mice even when
treatment is initiated late in life (58). The extent to which TOR signalling in neurons
contributes to the observed lifespan effects is unknown, but there is evidence that TOR
signalling and autophagy have significant effects on pathological protein aggregates
associated with age-dependent neuro degenerative diseases. For example, rapa mycin has
been shown to reduce toxic-aggregate formation and disease progression by increasing
autophagy in mouse and fly models of Huntington’s disease and tauopathy (59). These
results suggest that the TOR pathway may modulate pathological protein aggregation
associated with neurodegenerative disorders.
NIH-PA Author Manuscript
Accumulation of ubiquitylated protein aggregates can occur during normal human brain
ageing and reaches pathological levels in neurodegenerative disorders such as Alzheimer’s
disease and tauopathies. A recent study found that a mouse model of chronically reduced
proteasomal activity in the brain showed elevated concentrations of several proteins, some
of which had previously been found to alter expression in the brain in Alzheimer’s disease
(60). Furthermore, these mice had deficits in spatial memory, consistent with a potential role
for defective proteasome function in cognitive decline associated with Alzheimer’s disease.
Ubiquitylated protein aggregates are not as prevalent in other ageing tissues, which may
reflect the unusual longevity of post-mitotic neurons (which survive for an entire human
lifetime in a metabolically active state).
Insulin/IGF signalling
Reduced signalling through the insulin/IGF-1 signalling (IIS) pathway is a strongly
conserved mechanism of lifespan extension in worms, flies and mammals (reviewed in ref.
61). Polymorphisms in two IIS pathway genes, the IGF-1 receptor and the downstream
FOXO3 transcription factor, have been associated with longevity and healthy ageing in
NIH-PA Author Manuscript
humans (62–64). Importantly, reduced IIS specifically in the nervous system is sufficient to
extend lifespan in several model systems. In worms, for example, reduced IIS in the nervous
system accounts for a portion of the lifespan extension in IIS mutants (65,66). Furthermore,
ablation in the fly brain of specific neurosecretory cells that produce insulin-like peptides is
sufficient to extend lifespan (67).
In mammals, insulin and IGF-1 are neurotrophic and promote neuronal survival by
inhibiting apoptosis (68). Insulin and IGF-1 can also promote learning and memory in
humans and animal models (61,68). By contrast, reduction of IIS by neuron-specific
knockout of the insulin receptor substrate Irs2 is sufficient to extend mouse lifespan (69).
There is a dichotomy, therefore, between the neuroprotective effects of insulin and IGF-1
signalling and their apparently deleterious effects on organismal lifespan. Interestingly, the
effects on lifespan parallel the effects on neurodegenerative pathology. In worms, reduced
insulin signalling can ameliorate amyloid-β aggregation and cytotoxicity (70). Similarly,
knockout of Irs2 or the IGF-1 receptor can reduce cognitive impairment, neurodegeneration
and premature mortality in mouse models of Alzheimer’s disease (71,72). In patients with
Alzheimer’s disease, there is evidence of reduced expression of components of the IGF
NIH-PA Author Manuscript
The molecular basis of the beneficial effects of caloric restriction has recently begun to be
elucidated (80). The NAD+-dependent deacetylase SIR2 was one of the earliest genes to be
implicated in the response to caloric restriction, initially in a yeast model (81). Homologues
of Sir2 (called sirtuins) have subsequently been shown to mediate some of the effects of
caloric restriction in flies (82) and mammals (83,84). It is important to note, however, that
the potential roles of sirtuins in caloric restriction are controversial and context dependent
(see page 480), differing markedly across genetic backgrounds in yeast (85) and tissue types
in mice (86). Similarly, SIRT1 can have either beneficial or detrimental effects in the brain.
Evidence for the benefits of SIRT1 in brain ageing includes the finding that increased SIRT1
activity protects against axon degeneration after injury in a mouse mutant known as
Wallerian degeneration slow (87). SIRT1 also protects against amyloid-β toxicity in cell
culture and neurodegeneration in the p25/CDK5 mouse model, which recapitulates aspects
of Alzheimer’s disease pathology and tauopathy (88). By contrast, SIRT1 may also have
some detrimental effects, as Sirt1 knockout mice show reduced oxidative stress and
increased neuroprotection in the ageing brain even though lifespan is shortened (89). Further
studies are required to better elucidate the roles of sirtuins in brain ageing and their
NIH-PA Author Manuscript
Interestingly, the ASI neurons regulate energy metabolism in C. elegans and may thus
represent a functional analogue of the mammalian hypothalamus.
NIH-PA Author Manuscript
The hypothalamus functions as a central regulator of metabolism and energy use, and it
coordinates the physiological responses of the entire organism through hormonal signalling.
In mice, reducing the growth hormone signalling from the hypothalamic–pituitary axis
extends lifespan (93). Furthermore, overexpression of the mitochondrial uncoupling protein
UCP2 in specific cells in the murine hypothalamus is sufficient to extend lifespan (94).
These findings argue for a crucial role of hypothalamic hormonal signalling in the control of
organismal ageing.
Such hypothalamic regulation of hormonal pathways might have a role in cognitive decline
during brain ageing. The hypothalamus coordinates stress responses, in part through the
regulation of peripheral glucocorticoid secretion (95). Glucocorticoids can be sensed directly
by another part of the brain, the hippocampus, which then suppresses hypothalamic
stimulation of further glucocorticoid release in a negative feedback loop (Fig. 4). However,
excessive glucocorticoid production associated with chronic or severe stress may impair
hippocampal neuronal function and predispose the organism to neurodegeneration (96),
potentially disrupting the regulatory circuit that connects the hippocampus and the
hypothalamus. Furthermore, primary hippo campal neurodegeneration in individuals with
Alzheimer’s disease may also disrupt hippocampal–hypothalamic control of systemic
NIH-PA Author Manuscript
physiological functions (97). Other brain-systemic circuits yet to be discovered may further
integrate higher-order brain function with systemic physiology. Thus, primary degenerative
changes in the brain could contribute to systemic breakdown in the regulation of
glucocorticoids and other crucial hormones, such as IGF-1. These systemic changes may, in
turn, predispose the individual to further neurodegenerative changes, setting up a
progressive cycle of physiological and neurological decline (Fig. 4).
Future directions
The major risk factor for neurodegeneration and cognitive decline is the ageing of the brain.
Conserved pathways and mechanisms that control organismal ageing, such as insulin/IGF
signalling and mitochondrial function, can modulate pathology and cognitive decline in
mouse, fly and worm models of Alzheimer’s disease and other neurodegenerative disorders.
However, the role of these conserved pathways in the onset and progression of
neurodegenerative disorders in humans is still unclear. The resolution of this basic issue will
depend on future clinical interventions that target these pathways to ascertain their role in
both normal age-related cognitive decline and pathological neurodegeneration.
The role of the brain as a central integrator of physiological changes during ageing is just
NIH-PA Author Manuscript
beginning to be explored. Recent findings suggest that higher-order brain systems become
less efficient with age, with some degree of disconnection between brain areas that normally
function together in young adults. This may reflect, in part, gene expression changes that
affect synaptic function, axonal integrity and myelination. An intriguing question is whether
functional disconnection in the brain leads to disruption of brain-systemic feedback loops
involving crucial hormonal and autonomic systems. Such a loss of integrated function may
contribute to age-related physiological changes, such as hypertension and insulin resistance,
and predispose individuals to age-related pathological changes in the brain. It will be
exciting to explore the extent of these functional connections in future studies.
References
1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population:
NIH-PA Author Manuscript
prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119–1122. [PubMed:
12925369]
2. Andrews-Hanna JR, et al. Disruption of large-scale brain systems in advanced aging. Neuron
2007;56:924–935. [PubMed: 18054866] This paper reports that coordination of brain activity
between different brain regions becomes less robust in the ageing brain, suggesting a systems-level
breakdown of integrated function that correlates with poor cognitive performance
3. Cabeza R. Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol Aging
2002;17:85–100. [PubMed: 11931290] This paper shows that spreading activation of the human
prefrontal cortex from one hemisphere to both hemispheres may be a compensatory mechanism that
preserves function against age-related degenerative changes
4. Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev
Psychol 2009;60:173–196. [PubMed: 19035823]
5. Cabeza R, Anderson ND, Locantore JK, McIntosh AR. Aging gracefully: compensatory brain
activity in high-performing older adults. Neuroimage 2002;17:1394–1402. [PubMed: 12414279]
6. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008;3:41–66. [PubMed:
18039130]
7. Lu T, et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004;429:883–
891. [PubMed: 15190254] This paper shows that the ageing of the human cortex is characterized by
a distinct transcriptional signature that includes reduced expression of genes that mediate synaptic
NIH-PA Author Manuscript
plasticity and that correlates with age-dependent DNA damage to the promoters of these genes
8. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nature
Genet 2000;25:294–297. [PubMed: 10888876]
9. Jiang CH, Tsien JZ, Schultz PG, Hu Y. The effects of aging on gene expression in the hypothalamus
and cortex of mice. Proc Natl Acad Sci USA 2001;98:1930–1934. [PubMed: 11172053]
10. Blalock EM, et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel
processes correlated with cognitive impairment. J Neurosci 2003;23:3807–3819. [PubMed:
12736351]
11. Fraser HB, Khaitovich P, Plotkin JB, Paabo S, Eisen MB. Aging and gene expression in the
primate brain. PLoS Biol 2005;3:e274. [PubMed: 16048372]
12. Erraji-Benchekroun L, et al. Molecular aging in human prefrontal cortex is selective and
continuous throughout adult life. Biol Psychiatry 2005;57:549–558. [PubMed: 15737671]
13. Loerch PM, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE
2008;3:e3329. [PubMed: 18830410]
14. Small SA, Tsai WY, DeLaPaz R, Mayeux R, Stern Y. Imaging hippocampal function across the
human life span: is memory decline normal or not? Ann Neurol 2002;51:290–295. [PubMed:
11891823]
15. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal
NIH-PA Author Manuscript
neuronal loss in normal ageing and Alzheimer’s disease. Lancet 1994;344:769–772. [PubMed:
7916070]
16. Price JL, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.
Arch Neurol 2001;58:1395–1402. [PubMed: 11559310]
17. Gomez-Isla T, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild
Alzheimer’s disease. J Neurosci 1996;16:4491–4500. [PubMed: 8699259]
18. Rodrigue KM, Raz N. Shrinkage of the entorhinal cortex over five years predicts memory
performance in healthy adults. J Neurosci 2004;24:956–963. [PubMed: 14749440]
19. Zahn JM, et al. AGEMAP: a gene expression database for aging in mice. PLoS Genet 2007;3:e201.
[PubMed: 18081424]
20. Blalock EM, et al. Incipient Alzheimer’s disease: microarray correlation analyses reveal major
transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 2004;101:2173–2178.
[PubMed: 14769913]
21. Liang WS, et al. Alzheimer’s disease is associated with reduced expression of energy metabolism
genes in posterior cingulate neurons. Proc Natl Acad Sci USA 2008;105:4441–4446. [PubMed:
18332434]
NIH-PA Author Manuscript
22. Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in
Alzheimer’s disease and normal aging. J Neurosci 2008;28:1410–1420. [PubMed: 18256261]
23. Walker DW, Muffat J, Rundel C, Benzer S. Overexpression of a Drosophila homolog of
apolipoprotein D leads to increased stress resistance and extended lifespan. Curr Biol
2006;16:674–679. [PubMed: 16581512]
24. Sanchez D, et al. Loss of glial lazarillo, a homolog of apolipoprotein D, reduces lifespan and stress
resistance in Drosophila. Curr Biol 2006;16:680–686. [PubMed: 16581513]
25. Kalman J, McConathy W, Araoz C, Kasa P, Lacko AG. Apolipoprotein D in the aging brain and in
Alzheimer’s dementia. Neurol Res 2000;22:330–336. [PubMed: 10874678]
26. Sedensky MM, Morgan PG. Mitochondrial respiration and reactive oxygen species in
mitochondrial aging mutants. Exp Gerontol 2006;41:237–245. [PubMed: 16497463]
27. Rea SL, Ventura N, Johnson TE. Relationship between mitochondrial electron transport chain
dysfunction, development, and life extension in Caenorhabditis elegans. PLoS Biol 2007;5:e259.
[PubMed: 17914900]
28. Trifunovic A, et al. Premature ageing in mice expressing defective mitochondrial DNA
polymerase. Nature 2004;429:417–423. [PubMed: 15164064]
29. Kujoth GC, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian
aging. Science 2005;309:481–484. [PubMed: 16020738]
NIH-PA Author Manuscript
30. Schriner SE, et al. Extension of murine life span by overexpression of catalase targeted to
mitochondria. Science 2005;308:1909–1911. [PubMed: 15879174]
31. Lin SJ, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing
respiration. Nature 2002;418:344–348. [PubMed: 12124627]
32. Wallace DC, et al. Familial mitochondrial encephalomyopathy (MERRF): genetic,
pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell
1988;55:601–610. [PubMed: 3180221]
33. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with
mitochondrial myopathies. Nature 1988;331:717–719. [PubMed: 2830540]
34. Sanchez-Blanco A, Fridell YW, Helfand SL. Involvement of Drosophila uncoupling protein 5 in
metabolism and aging. Genetics 2006;172:1699–1710. [PubMed: 16387864]
35. Branicky R, Bénard C, Hekimi S. clk-1, mitochondria, and physiological rates. BioEssays
2000;22:48–56. [PubMed: 10649290]
36. Lee SS, et al. A systematic RNAi screen identifies a critical role for mitochondria in C. elegans
longevity. Nature Genet 2003;33:40–48. [PubMed: 12447374]
37. Dillin A, et al. Rates of behavior and aging specified by mitochondrial function during
development. Science 2002;298:2398–2401. [PubMed: 12471266] This paper provided the first
systematic demonstration of a role for the electron transport chain in metazoan lifespan control,
NIH-PA Author Manuscript
43. Park SK, et al. Gene expression profiling of aging in multiple mouse strains: identification of aging
biomarkers and impact of dietary antioxidants. Aging Cell 2009;8:484–495. [PubMed: 19555370]
44. Liu J, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA
NIH-PA Author Manuscript
oxidation: partial reversal by feeding acetyl-l-carnitine and/or R-α-lipoic acid. Proc Natl Acad Sci
USA 2002;99:2356–2361. [PubMed: 11854529] This paper reports that memory loss in aged rats
can be reversed by restoring mitochondrial function with dietary mitochondrial substrates and
antioxidants
45. Oberdoerffer P, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene
expression during aging. Cell 2008;135:907–918. [PubMed: 19041753]
46. O’Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and
SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet
2008;4:e1000155. [PubMed: 18704159]
47. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000;14:1021–
1026. [PubMed: 10809662]
48. Curran SP, Ruvkun G. Lifespan regulation by evolutionarily conserved genes essential for
viability. PLoS Genet 2007;3:e56. [PubMed: 17411345]
49. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is
associated with chromatin remodelling. Nature 2007;447:178–182. [PubMed: 17468743] This
paper shows that memory loss may be related to altered chromatin structure in a mouse model of
neurodegeneration and can be reversed in part with histone deacetylase inhibitors. This raises the
possibility of epigenetic approaches to the treatment of human neurodegenerative disorders
50. Melendez A, et al. Autophagy genes are essential for dauer development and life-span extension in
NIH-PA Author Manuscript
58. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Nature 2009;460:392–395. [PubMed: 19587680]
59. Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine
expansions in fly and mouse models of Huntington disease. Nature Genet 2004;36:585–595.
[PubMed: 15146184]
60. Fischer DF, et al. Long-term proteasome dysfunction in the mouse brain by expression of aberrant
ubiquitin. Neurobiol Aging 2009;30:847–863. [PubMed: 18760506]
61. Broughton S, Partridge L. Insulin/IGF-like signalling, the central nervous system and aging.
Biochem J 2009;418:1–12. [PubMed: 19159343]
62. Flachsbart F, et al. Association of FOXO3A variation with human longevity confirmed in German
centenarians. Proc Natl Acad Sci USA 2009;106:2700–2705. [PubMed: 19196970]
63. Suh Y, et al. Functionally significant insulin-like growth factor I receptor mutations in
centenarians. Proc Natl Acad Sci USA 2008;105:3438–3442. [PubMed: 18316725]
64. Willcox BJ, et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad
Sci USA 2008;105:13987–13992. [PubMed: 18765803]
65. Libina N, Berman JR, Kenyon C. Tissue-specific activities of C. elegans DAF-16 in the regulation
NIH-PA Author Manuscript
[PubMed: 18479783]
74. Haigis MC, Guarente LP. Mammalian sirtuins — emerging roles in physiology, aging, and calorie
restriction. Genes Dev 2006;20:2913–2921. [PubMed: 17079682]
75. Colman RJ, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science
2009;325:201–204. [PubMed: 19590001] This paper reports that caloric restriction increases
longevity in primates, delays the onset of age-related diseases and reduces age-related brain
atrophy
76. Ingram DK, Weindruch R, Spangler EL, Freeman JR, Walford RL. Dietary restriction benefits
learning and motor performance of aged mice. J Gerontol 1987;42:78–81. [PubMed: 3794202]
77. Stewart J, Mitchell J, Kalant N. The effects of life-long food restriction on spatial memory in
young and aged Fischer 344 rats measured in the eight-arm radial and the Morris water mazes.
Neurobiol Aging 1989;10:669–675. [PubMed: 2628778]
78. Witte AV, Fobker M, Gellner R, Knecht S, Flöel A. Caloric restriction improves memory in
elderly humans. Proc Natl Acad Sci USA 2009;106:1255–1260. [PubMed: 19171901]
79. Halagappa VK, et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral
deficits in the triple-transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2007;26:212–
220. [PubMed: 17306982]
80. Mair W, Dillin A. Aging and survival: the genetics of life span extension by dietary restriction.
NIH-PA Author Manuscript
87. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent
axonal degeneration. Science 2004;305:1010–1013. [PubMed: 15310905]
88. Kim D, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s
NIH-PA Author Manuscript
96. Conrad CD. Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability
hypothesis. Rev Neurosci 2008;19:395–411. [PubMed: 19317179]
97. Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on
the human hypothalamus. Brain Res Rev 2008;57:531–553. [PubMed: 17524488]
98. Zahn JM, et al. Transcriptional profiling of aging in human muscle reveals a common aging
signature. PLoS Genet 2006;2:e115. [PubMed: 16789832]
99. Rodwell GE, et al. A transcriptional profile of aging in the human kidney. PLoS Biol 2004;2:e427.
[PubMed: 15562319]
100. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the
ketogenic diet, and ketone bodies. Brain Res Rev 2009;59:293–315. [PubMed: 18845187]
NIH-PA Author Manuscript
considerably reduced in aged individuals. (Images reproduced, with permission, from ref. 2.)
Bottom: hypothetical connections between areas of the mPFC, pC and LP may mediate the
coordinated activation in young adults, whereas declining function of such connections
could underlie the observed disruption in coordinated activity in ageing brains. (Images
courtesy of C. Koch, California Institute of Technology, Pasadena.) b, Positron emission
tomography shows that young adults performing a memory test exhibit right-lateralized
brain activation. Aged adults with poor performance in this test also had right-lateralized
PFC activity, but aged adults with good performance showed bilateral activation. Thus,
recruitment of additional brain areas may compensate for age-dependent functional decline
in the primary areas subserving cognitive abilities (3,5). (Images reproduced, with
permission, from ref. 5.)
NIH-PA Author Manuscript
ROS production, which, in turn, may contribute to further mitochondrial damage. Damaged
mitochondria can be cleared by autophagy, which is promoted by CR and inhibited by TOR
signalling. CR improves overall mitochondrial function, in part, by promoting mitochondrial
biogenesis and reducing ROS production (100). ROS can damage other crucial
macromolecules, such as DNA and proteins. Unrepaired DNA damage may give rise to
epigenetic changes and gene silencing and may exacerbate mitochondrial impairment by
reducing the expression of nuclear-encoded mitochondrial genes. ROS can also modify
proteins, leading to protein unfolding and aggregation. Modified proteins can be removed by
a number of degradative pathways, including the ubiquitin proteasome pathway. Inadequate
clearance may lead to the accumulation of toxic protein aggregates. The dynamics of protein
clearance and aggregate formation may be modulated by the IIS pathway and by SIRT1 and
CR. The accumulation of damaged and toxic proteins may also be modified through the
regulation of messenger RNA translation by TOR signalling and CR.
NIH-PA Author Manuscript
mechanistically.
Table 1
Signalling pathways that influence ageing in model organisms and brain ageing in mammals
NIH-PA Author Manuscript
Table 2
Evolutionary conservation of gene expression changes during brain ageing
Gene category Human (brain) Rhesus macaque (brain) Rat (brain) Mouse (brain) Fly (organism) Worm (organism)
Bishop et al.
Stress response ↑ ↑ ↑ ↑ ↑ ↑
Mitochondria ↓ ↓ ↓ ↓↑ ↓ ↓
Neural plasticity/synaptic function ↓ ↓ ↓ ↓ – –
Inhibitory interneuron function ↓ ↓ – – – –
Ubiquitin–proteasome pathway ↓ ↓ – ↓ – –
Immune/inflammatory response ↑ – ↑ ↑ ↑ –
Metal ion homeostasis ↑ – ↑ – – –
Myelin-related proteins ↑ – ↑ – – –
Glial genes ↑ – ↑ – – –
Some gene categories, such as those involved in stress responses and mitochondrial function, show conserved changes during ageing, whereas others, such as inhibitory interneuron function, exhibit primate-
specific changes. An upward arrow indicates that expression increases with age; a downward arrow indicates that expression decreases with age; and a dash indicates that no change in expression with age is
detected. In the ageing mouse brain, different subsets of mitochondrial genes are either age-upregulated or age-downregulated (13).